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Introduction
The threat of antimicrobial resistance 
has been identiﬁed as one of the major 
challenges facing public health by numerous 
organisations and scientiﬁc societies 
including the World Health Organisation.1 
4HE CHALLENGE OF THE h-ICROBIAL 4HREATv HAS 
also been recognised by the European Union 
through numerous communications over the 
past years culminating in the adoption of 
a community strategy.2 Indeed, antibiotic 
resistance has become one of the most 
pressing challenges in modern health care 
and has signiﬁcant repercussions on both the 
patient as well as the health care system. 
Since most infections need to be treated 
empirically, before microbiology culture and 
sensitivity results are available a few days 
later, it is critical that the initial choice of 
antibiotic is correct. If levels of resistance 
in pathogenic bacteria are high, the risk 
of incorrect initial treatment becomes 
signiﬁcant. In milder infections this may 
not be too problematic because treatment 
could be adjusted after laboratory results 
are known. However this is not the case 
in potentially life threatening infections, 
such as sepsis. These must be treated 
immediately and effectively, if the risk of 
serious complications as well as mortality is 
to be reduced.3 Antibiotic resistance also has 
a major impact on health care economics, 
especially in hospitals.4,5 Patients with 
resistant health care acquired infections 
need to stay longer than originally planned 
and often require second and third line 
antibiotics for treatment, which invariably 
come at a much higher cost. Indeed a single 
MRSA bacteraemia at Mater Dei Hospital can 
result in more than €10,000 of additional 
costs.
Antibiotic use as a driver of resistance
Antibiotic use remains one of the most 
important drivers causing antimicrobial 
resistance, especially in the community.6 
Therefore intervention needs to be focused 
on improved antibiotic stewardship. 
Judicious use of antibiotics has two main 
cornerstones: in the ﬁrst instance antibiotics 
should only be used for bacterial infections. 
This seems totally obvious but is indeed 
one of the main reasons why resistance 
is increasing all over the world. The use 
of antibiotics for upper respiratory tract 
infections, which are commonly of a viral 
aetiology, is reported to some degree or 
another within every country. However, a 
recent Eurosurveillance survey identiﬁed 
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Malta as the second highest European 
antibiotic consumer.7 Furthermore around 
75% of these prescriptions were for colds, 
ﬂu, and sore throat all of which are primarily 
viral conditions. Use of antibiotics in such 
situations will not improve recovery but it 
will destroy sensitive bacterial commensal 
ﬂora in the patient. Mutant resistant 
strains, normally kept under control by 
commensals, will proliferate to become 
the predominant organisms. They in turn 
can either be cross transmitted to other 
individuals or alternatively cause secondary 
infections within that same patient. 
Indeed studies have shown that following 
exposure to macrolides, macrolide resistant 
bacteria immediately develop within the 
upper respiratory tract and can persist for 
as long as six months after treatment is 
stopped.8 Another area of antibiotic misuse 
relates to topical creams and ointment. It 
is not uncommon for these formulations to 
be used for non-infective dermatological 
conditions, such as eczema or insect 
bites, or alternatively boils or abscesses 
where topical antibiotics are unlikely to 
penetrate sufﬁciently. The other major 
driver of resistance is use of wide spectrum 
antibiotics. The majority of infections in 
the community can be predicted in terms 
of the causative organisms. Skin and soft 
tissue infections are in the main caused by 
Staphylococcus aureus. The major pathogen 
behind community acquired respiratory 
infections is predominantly Streptococcus 
pneumoniae whereas E. coli causes more 
than 85% of urinary tract infections. It 
is therefore possible, through a basic 
knowledge of resistance patterns, to use 
narrow spectrum antibiotics for each of these 
conditions which target these pathogenic 
bacteria speciﬁcally. 
Local antimicrobial resistance 
epidemiology
The epidemiology of antibiotic resistance 
in Malta has been identiﬁed as a result of 
several surveillance initiatives as well as 
participation in European network activities. 
Resistance in local community infections is 
reaching worrying levels.9 Most perturbing 
are the levels of community MRSA as well as 
resistant E. coli. In the case of community 
MRSA, carriage rate amongst healthy 
individuals who have never required hospital 
treatment has been found to be more than 
8% (Scerri J, University of Malta thesis - 
2011). It is one of the highest recorded 
levels in the world. Most of the strains 
identiﬁed in the study were characteristically 
a single clone. This clone has already been 
described and dubbed the Malta clone; it is 
resistant to beta-lactams as well as fusidic 
acid.10 Gram negative bacteria, especially E. 
coli, are also showing increasing resistance 
to beta-lactams as well as ciproﬂoxacin. 
The main drivers of these two phenomena 
are again thought to be antibiotic use. In 
the case of MRSA, the clonal characteristics 
suggests a link with misuse and overuse 
of fusidic acid creams and ointments. 
E. coli resistance has shown association 
with use of beta-lactam antibiotics in the 
community, especially second generation 
cephalosporins.11 
It is however encouraging that the 
most important community pathogen, 
Streptococcus pneumoniae, remains relatively 
sensitive to penicillin. This is very important 
since it is the main bacterial pathogen 
causing lower and upper respiratory tract 
infections of bacterial origin. Since most 
antibiotics in the community are prescribed 
for these conditions, there is a great window 
of opportunity to address our current 
prescribing habits and reduce the risk of 
further resistance development. The amount 
of wide spectrum antibiotics prescribed 
in the community in Malta is difﬁcult to 
understand and even less to justify. More 
than 80% of antibiotics used in ambulatory 
care fall in one of four groups: wide 
spectrum penicillins with beta-lactamase 
inhibitor, second generation cephalosporins, 
ﬂuoroquinolones and macrolides.11 This 
is clearly not in line with the local 
epidemiological resistance picture. 
Antibiotic stewardship
In order to address these issues, 
the National Antibiotic Committee has 
published its ﬁrst set of guidelines for 
prescribing of antibiotics in ambulatory 
care. The guidelines are available on the 
Committee’s weblink: www.nacmalta.info. 
They aim to provide a tool that will allow 
better prescribing decisions in terms of 
what patients are given for presumptive 
infectious conditions. The guidelines 
include algorithms to assist physicians in 
recognising upper respiratory infections 
of likely viral origin where antibiotics are 
not required. Similarly the dermatological 
section lists the common skin conditions 
and identiﬁes those few indications where 
topical antibiotics are actually effective. 
The guidelines also introduce the concept 
of delayed prescription in which a physician 
post-dates a prescription by 2 or 3 days and 
counsels the patient to refer to a pharmacy 
for its dispensing only if the condition is 
not improving or has deteriorated after that 
period of time.12 Above all, the guidelines 
emphasise the use of narrow spectrum 
antibiotics, of which the use of amoxicillin 
for most upper respiratory tract infections is 
a key feature. This requires a major culture 
change since our knee-jerk has clearly been 
to resort to wide spectrum antibiotics for 
both upper respiratory as well as urinary 
infections. However, as clearly identiﬁed in 
the extensive list of references and evidence 
base that accompanies the guidelines, 
treatment of most ambulatory care infections 
is equally effective with narrow as it is 
with the wider spectrum formulations. The 
only difference is that the former are far 
less of a driver of resistance. Furthermore 
nitrofurantoin is actually superior in terms 
of antimicrobial susceptibility for urinary 
tract bacteria causing simple cystitis. Finally 
use of non-antibiotic topical dermatological 
creams, such as hydrogen peroxide, offers an 
equivalent therapeutic option for minor skin 
infections. The guidelines will be updated 
in line with emerging literature as well as 
changing local resistance patterns.
Practice points
s  !NTIBIOTIC RESISTANCE IN THE LOCAL COMMUNITY ISOLATES OF Staphylococcus aureus and E. 




and focused by avoiding treating viral conditions and utilising narrower spectrum 
formulations
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unlikely (boils and abscesses)
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Conclusion
We are literally at a cross road. The 
increase in antibiotic resistance in Malta  
over the past decade has been extremely 
worrying and has impacted on the 
development of resistance in ambulatory 
care. Nevertheless we have not yet reached a 
situation where resistance cannot be tackled 
or even possibly reversed. This, however, 
requires a change in habits that developed 
over many decades. Antibiotic guidelines 
have been shown to be effective in 
improving prescribing in other countries.13,14 
Hopefully the national guidelines will serve 
as a useful tool to achieve this goal locally. 
Our patients, present and future, deserve 
nothing less.
The National Antibiotic Committee 
advises the Superintendent of Public Health 
on matters related to antibiotic use and 
resistance. Its current members are: Dr 
Michael Borg, Dr Anthony Azzopardi, Dr 
Susan Chircop, Prof Paul Cuscheri, Dr Tanya 
Melillo, Dr Tonio Piscopo, Ms Isabelle Zahra 
Pulis, Dr Maria Cordina, Dr Gunther Abela and 
Mr Peter Zarb. The Comittee can be contacted 
on: nac.mhec@gov.mt
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